歌礼制药-B(01672)发布中期业绩股东应占亏损3.2亿元同比增加263.5%

智通财经

Aug 31

智通财经APP讯，歌礼制药-B(01672)发布截至2026年6月30日止六个月业绩，该集团取得收入总额人民币5297.9万元(单位下同)，同比减少48.9%;研发成本3.42亿元，同比增加132.7%;公司权益股东应占亏损3.2亿元，同比增加263.5%;每股亏损30.74分。

于报告期内及直至本公告日期，集团在免疫性疾病管线方面取得重大进展：ASC50为一款IL-17A口服小分子抑制剂，已完成健康受试者美国I期SAD研究及轻度至中度斑块状银屑病患者为期28天的美国I期概念验证研究(POC) (200 mg QD)。人体数据表明，ASC50有望成为同类首创及同类最佳口服小分子IL-17A抑制剂。ASC51为一款强效、选择性及每日一次口服STAT6降解剂并已具备向FDA 提交IND申请条件的候选药物。ASC51已完成FDA IND所需的全部准备研究，并有望成为继KT-62后同类第二款STAT6口服小分子降解剂。ASC52有望成为同类最佳IL-17AA、AF及FF口服环肽拮抗剂，预计将于2026年第四季度向FDA递交IND。ASC52有望成为继PN-881后同类第二款IL-17AA、AF及FF口服环肽拮抗剂。

该等成就凸显集团强大的研发能力、卓越的执行力以及研发全球同类最佳╱全球同类首创管线药物以解决未被满足临床需求的长期承诺。

研发开支大幅增加主要由于集团对推进其全面代谢性疾病管线(包括小分子及多肽)的战略承诺。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2663006583"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2663006583\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2663006583?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-31 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2663006583","market":"us","top_or_hot":-1,"title":"歌礼制药-B(01672)发布中期业绩 股东应占亏损3.2亿元 同比增加263.5%","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/01672\">歌礼制药-B</a>(01672)发布截至2026年6月30日止六个月业绩，该集团取得收入总额人民币5297.9万元(单位下同)，同比减少48.9%;研发成本3.42亿元，同比增加132.7%;公司权益股东应占亏损3.2亿元，同比增加263.5%;每股亏损30.74分。</p><p>于报告期内及直至本公告日期，集团在免疫性疾病管线方面取得重大进展：ASC50为一款IL-17A口服小分子抑制剂，已完成健康受试者美国I期SAD研究及轻度至中度斑块状银屑病患者为期28天的美国I期概念验证研究(POC) (200 mg QD)。人体数据表明，ASC50有望成为同类首创及同类最佳口服小分子IL-17A抑制剂。ASC51为一款强效、选择性及每日一次口服STAT6降解剂并已具备向FDA 提交IND申请条件的候选药物。ASC51已完成FDA IND所需的全部准备研究，并有望成为继KT-62后同类第二款STAT6口服小分子降解剂。ASC52有望成为同类最佳IL-17AA、AF及FF口服环肽拮抗剂，预计将于2026年第四季度向FDA递交IND。ASC52有望成为继PN-881后同类第二款IL-17AA、AF及FF口服环肽拮抗剂。</p><p>该等成就凸显集团强大的研发能力、卓越的执行力以及研发全球同类最佳╱全球同类首创管线药物以解决未被满足临床需求的长期承诺。</p><p>研发开支大幅增加主要由于集团对推进其全面代谢性疾病管线(包括小分子及多肽)的战略承诺。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>歌礼制药-B(01672)发布中期业绩 股东应占亏损3.2亿元 同比增加263.5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n歌礼制药-B(01672)发布中期业绩 股东应占亏损3.2亿元 同比增加263.5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-31 21:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1489861.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，歌礼制药-B(01672)发布截至2026年6月30日止六个月业绩，该集团取得收入总额人民币5297.9万元(单位下同)，同比减少48.9%;研发成本3.42亿元，同比增加132.7%;公司权益股东应占亏损3.2亿元，同比增加263.5%;每股亏损30.74分。于报告期内及直至本公告日期，集团在免疫性疾病管线方面取得重大进展：ASC50为一款IL-17A口服小分子抑制剂，已完成...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1489861.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1489861.html","article_id":"2663006583","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2663006583","pubTimestamp":1788182651,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，歌礼制药-B 发布截至2026年6月30日止六个月业绩，该集团取得收入总额人民币5297.9万元，同比减少48.9%;研发成本3.42亿元，同比增加132.7%;公司权益股东应占亏损3.2亿元，同比增加263.5%;每股亏损30.74分。人体数据表明，ASC50有望成为同类首创及同类最佳口服小分子IL-17A抑制剂。ASC51为一款强效、选择性及每日一次口服STAT6降解剂并已具备向FDA 提交IND申请条件的候选药物。ASC52有望成为同类最佳IL-17AA、AF及FF口服环肽拮抗剂，预计将于2026年第四季度向FDA递交IND。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","01672":"歌礼制药-B","01477":"欧康维视生物-B","BK1191":"制药","BK1515":"抗疫概念"},"translate_title":"Ascletis-B (01672) released its interim results, reporting a loss attributable to shareholders of RMB 320 million, an increase of 263.5% year-on-year.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1.5,"01477":1.5},"content_text":"智通财经APP讯，歌礼制药-B(01672)发布截至2026年6月30日止六个月业绩，该集团取得收入总额人民币5297.9万元(单位下同)，同比减少48.9%;研发成本3.42亿元，同比增加132.7%;公司权益股东应占亏损3.2亿元，同比增加263.5%;每股亏损30.74分。于报告期内及直至本公告日期，集团在免疫性疾病管线方面取得重大进展：ASC50为一款IL-17A口服小分子抑制剂，已完成健康受试者美国I期SAD研究及轻度至中度斑块状银屑病患者为期28天的美国I期概念验证研究(POC) (200 mg QD)。人体数据表明，ASC50有望成为同类首创及同类最佳口服小分子IL-17A抑制剂。ASC51为一款强效、选择性及每日一次口服STAT6降解剂并已具备向FDA 提交IND申请条件的候选药物。ASC51已完成FDA IND所需的全部准备研究，并有望成为继KT-62后同类第二款STAT6口服小分子降解剂。ASC52有望成为同类最佳IL-17AA、AF及FF口服环肽拮抗剂，预计将于2026年第四季度向FDA递交IND。ASC52有望成为继PN-881后同类第二款IL-17AA、AF及FF口服环肽拮抗剂。该等成就凸显集团强大的研发能力、卓越的执行力以及研发全球同类最佳╱全球同类首创管线药物以解决未被满足临床需求的长期承诺。研发开支大幅增加主要由于集团对推进其全面代谢性疾病管线(包括小分子及多肽)的战略承诺。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}